Planned sales, announced before they happen
9 trading plans running, 46 Form 144 notices for $120.9M
Plans running now
9
Kelly Kramer, Andrew Dickinson, Keeley Cain Wettan, Anthony Welters, Jeffrey Bluestone, Daniel P. O’Day, Deborah Telman, Johanna Mercier
What GILD's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans
Plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Kelly Kramer Board of Directors |
Adopted 10b5-1 plan | Aug 13, 2026 | up to 19,872 | Aug 10, 2027 | 10-Q Oct 30, 2026 |
What the company wroteOn August 13, 2026, Kelly Kramer, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 19,872 shares of our common stock through August 10, 2027, subject to certain conditions. | |||||
| Andrew Dickinson Chief Financial Officer |
Adopted 10b5-1 plan | Aug 7, 2026 | up to 272,582 | May 31, 2028 | 10-Q Oct 30, 2026 |
What the company wroteOn August 7, 2026, Andrew Dickinson, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 272,582 shares of our common stock through May 31, 2028, subject to certain conditions. | |||||
| Keeley Cain Wettan Executive Vice President and General Counsel, Legal and Compliance |
Adopted 10b5-1 plan | Aug 7, 2026 | up to 1,860 | Sep 30, 2027 | 10-Q Oct 30, 2026 |
What the company wroteOn August 7, 2026, Keeley Cain Wettan, our Executive Vice President and General Counsel, Legal and Compliance, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell, subject to certain conditions, through September 30, 2027, the net shares of our common stock to be issued to Ms. Cain Wettan after the satisfaction of applicable withholding taxes following the potential vesting and settlement of (a) 14,185 restricted stock units and (b) up to 1,860 performance stock units. | |||||
| Anthony Welters Board of Directors |
Adopted 10b5-1 plan | May 27, 2026 | up to 18,000 | Dec 31, 2026 | 10-Q Aug 6, 2026 |
What the company wroteOn May 27, 2026, Anthony Welters, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 18,000 shares of our common stock through December 31, 2026, subject to certain conditions. | |||||
| Jeffrey Bluestone Board of Directors |
Adopted 10b5-1 plan | May 20, 2026 | up to 10,000 | Jan 31, 2027 | 10-Q Aug 6, 2026 |
What the company wroteOn May 20, 2026, Jeffrey Bluestone, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 10,000 shares of our common stock through January 31, 2027, subject to certain conditions. | |||||
| Daniel P. O’Day Chief Executive Officer |
Adopted 10b5-1 plan | Feb 25, 2026 | up to 747,975 | May 29, 2027 | 10-Q May 7, 2026 |
What the company wroteOn February 25, 2026, Daniel P. O’Day, our Chief Executive Officer and Chairman of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 747,975 shares of our common stock through May 29, 2027, subject to certain conditions. | |||||
| Kelly Kramer member of our Board of Directors |
Adopted 10b5-1 plan | Aug 27, 2025 | up to 5,611 | Aug 19, 2026 | 10-Q Nov 7, 2025 |
What the company wroteOn August 27, 2025, Kelly Kramer, a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 5,611 shares of our common stock through August 19, 2026, subject to certain conditions. | |||||
| Deborah Telman Executive Vice President of Corporate Affairs |
Adopted 10b5-1 plan | Aug 13, 2025 | up to 91,861 | Nov 16, 2026 | 10-Q Nov 7, 2025 |
What the company wroteOn August 13, 2025, Deborah Telman, our Executive Vice President of Corporate Affairs and General Counsel, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 91,861 shares of our common stock through November 16, 2026, subject to certain conditions. | |||||
| Daniel P. O’Day Chief Executive Officer |
Adopted 10b5-1 plan | Feb 28, 2025 | up to 351,280 | May 29, 2026 | 10-Q May 7, 2025 |
What the company wroteOn February 28, 2025, Daniel P. O’Day, our Chief Executive Officer and Chairman of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 351,280 shares of our common stock through May 29, 2026, subject to certain conditions. | |||||
| Johanna Mercier Chief Commercial Officer |
Adopted 10b5-1 plan | Feb 20, 2025 | up to 266,000 | Feb 19, 2027 | 10-Q May 7, 2025 |
What the company wroteOn February 20, 2025, Johanna Mercier, our Chief Commercial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 266,000 shares of our common stock through February 19, 2027, subject to certain conditions. | |||||
| Jeffrey A. Bluestone, Ph.D. member of our Board of Directors |
Adopted 10b5-1 plan | Feb 13, 2025 | up to 10,000 | Feb 13, 2026 | 10-Q May 7, 2025 |
What the company wroteOn February 13, 2025, Jeffrey A. Bluestone, Ph.D., a member of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 10,000 shares of our common stock through February 13, 2026, subject to certain conditions. | |||||
| Andrew Dickinson Chief Financial Officer |
Adopted 10b5-1 plan | Aug 29, 2024 | up to 695,164 | Nov 29, 2026 | 10-Q Nov 12, 2024 |
What the company wroteOn August 29, 2024, Andrew Dickinson, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 695,164 shares of our common stock through November 29, 2026, subject to certain conditions. | |||||
| Merdad V. Parsey Chief Medical Officer |
Adopted 10b5-1 plan | Aug 28, 2024 | up to 395,164 | Apr 8, 2025 | 10-Q Nov 12, 2024 |
What the company wroteOn August 28, 2024, Merdad V. Parsey, M.D., Ph.D., our Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell, subject to certain conditions, through April 8, 2025: (a) up to 395,164 shares of our common stock; and (b) 40% of the net vested shares of our common stock to be issued to Dr. Parsey in connection with the potential vesting and settlement of certain performance stock units. | |||||
| Johanna Mercier Chief Commercial Officer |
Adopted 10b5-1 plan | Apr 30, 2024 | up to 49,630 | Apr 30, 2025 | 10-Q Aug 8, 2024 |
What the company wroteOn April 30, 2024, Johanna Mercier, our Chief Commercial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 49,630 shares of our common stock through April 30, 2025, subject to certain conditions. | |||||
| Merdad V. Parsey Chief Medical Officer |
Adopted 10b5-1 plan | Nov 9, 2023 | up to 56,624 | 365 days | 10-K Feb 23, 2024 |
What the company wroteOn November 9, 2023, Merdad V. Parsey, M.D., PhD., our Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell, subject to certain conditions, through November 8, 2024: (a) up to 29,393 shares of our common stock; (b) the total number of shares of our common stock sufficient to cover costs and fees and to satisfy applicable withholding taxes in connection with the exercise of 64,376 stock options; and (c) 25% of net shares of our common stock to be issued to Dr. Parsey after the satisfaction of applicable withholding taxes following the potential vesting and settlement of up to 56,624 performance shares. | |||||
Show the other 7 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.
Form 144
Notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | KEELEY M CAIN WETTAN Officer |
3,399 | $570K | Restricted Stock Units | adopted Aug 7, 2026 | 3,399 shares from Nov 6, 2026 |
| Nov 4, 2026 | DANIEL O'DAY Director, Officer |
112,429 | $18.8M | Exercise of Stock Options | adopted Feb 25, 2026 | 112,429 shares from Nov 4, 2026 |
| Oct 30, 2026 | DANIEL O'DAY Director, Officer |
45,881 | $7.6M | Exercise of Stock Options; Performance Stock Units | adopted Feb 25, 2026 | 143,310 shares from Oct 30, 2026 |
| Oct 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $469K | Performance Shares | adopted Feb 20, 2025 | 3,000 shares from Oct 15, 2026 |
| Oct 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $469K | Performance Shares | adopted Aug 29, 2024 | 3,000 shares from Oct 15, 2026 |
| Sep 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $433K | Performance Shares | adopted Feb 20, 2025 | 6,000 shares from Sep 15, 2026 |
| Sep 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $436K | Performance Shares | adopted Aug 29, 2024 | 6,000 shares from Sep 15, 2026 |
| Aug 26, 2026 | ANTHONY WELTERS Director |
18,000 | $2.7M | Exercise of Stock Options | adopted May 27, 2026 | 18,000 shares from Aug 26, 2026 |
| Aug 20, 2026 | JEFFREY BLUESTONE Director |
5,000 | $738K | Exercise of Stock Options | adopted May 20, 2026 | 5,000 shares from Aug 20, 2026 |
| Aug 17, 2026 | JOHANNA MERCIER Officer |
28,000 | $3.9M | Performance Shares; Stock Option Exercise | adopted Feb 20, 2025 | 31,000 shares from Aug 17, 2026 |
| Aug 17, 2026 | ANDREW DICKINSON Officer |
3,000 | $415K | Performance Shares | adopted Aug 29, 2024 | 6,000 shares from Aug 17, 2026 |
| Aug 3, 2026 | DANIEL O'DAY Director, Officer |
55,000 | $7.2M | Restricted Stock Units and Performance Stock Units | adopted Feb 25, 2026 | 30,000 shares from Aug 3, 2026 |
| Jul 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $390K | Performance Shares | adopted Feb 20, 2025 | 3,000 shares from Jul 15, 2026 |
| Jul 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $390K | Performance Shares | adopted Aug 29, 2024 | 3,000 shares from Jul 15, 2026 |
| Jun 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $376K | Performance Shares | adopted Aug 29, 2024 | 6,000 shares from Jun 15, 2026 |
| Jun 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $372K | Performance Shares | adopted Feb 20, 2025 | 6,000 shares from Jun 15, 2026 |
| Jun 1, 2026 | DANIEL O'DAY Director, Officer |
35,000 | $4.7M | Performance Stock Units | adopted Feb 25, 2026 | 30,000 shares from Jun 1, 2026 |
| May 15, 2026 | JOHANNA MERCIER Officer |
28,000 | $3.7M | Performance Shares; Restricted Stock; Stock Option Exercise | adopted Feb 20, 2025 | 28,000 shares from May 15, 2026 |
| May 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $397K | Performance Shares | adopted Aug 29, 2024 | 3,000 shares from May 15, 2026 |
| Apr 28, 2026 | DANIEL O'DAY Officer, Director |
10,000 | $1.3M | Performance Shares | adopted Feb 28, 2025 | 10,000 shares from Apr 28, 2026 |
| Apr 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $423K | Restricted Stock | adopted Feb 20, 2025 | 28,000 shares from May 15, 2026 |
| Apr 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $423K | Performance Shares | adopted Aug 29, 2024 | 3,000 shares from May 15, 2026 |
| Mar 27, 2026 | DANIEL O'DAY Officer, Director |
10,000 | $1.4M | Performance Shares | adopted Feb 28, 2025 | none found |
| Mar 16, 2026 | JOHANNA MERCIER Officer |
3,000 | $433K | Restricted Stock | adopted Feb 20, 2025 | none found |
| Mar 16, 2026 | ANDREW DICKINSON Officer |
3,000 | $433K | Performance Shares | adopted Aug 29, 2024 | none found |
| Feb 27, 2026 | DANIEL O'DAY Officer, Director |
10,000 | $1.4M | Restricted Stock | adopted Feb 28, 2025 | none found |
| Feb 17, 2026 | JOHANNA MERCIER Officer |
28,000 | $4.3M | Restricted Stock; Stock Option Exercise | adopted Feb 20, 2025 | none found |
| Feb 17, 2026 | ANDREW DICKINSON Officer |
3,000 | $463K | Performance Shares | adopted Aug 29, 2024 | none found |
| Feb 5, 2026 | DANIEL O'DAY Officer, Director |
115,640 | $17.3M | Stock Option Exercise | adopted Feb 28, 2025 | none found |
| Jan 28, 2026 | DANIEL O'DAY Officer, Director |
10,000 | $1.4M | Performance Shares | adopted Feb 28, 2025 | none found |
| Jan 23, 2026 | DANIEL O'DAY Officer, Director |
115,640 | $15.6M | Stock Option Exercise | adopted Feb 28, 2025 | none found |
| Jan 22, 2026 | DEBORAH TELMAN Officer |
29,215 | $3.8M | Exercise of Stock Options; Restricted Stock Units | adopted Aug 13, 2025 | none found |
| Jan 20, 2026 | JEFFREY BLUESTONE Director |
5,000 | $618K | Stock Option Exercise | adopted Feb 13, 2025 | none found |
| Jan 15, 2026 | JOHANNA MERCIER Officer |
3,000 | $373K | Performance Shares; Restricted Stock | adopted Feb 20, 2025 | none found |
| Jan 15, 2026 | ANDREW DICKINSON Officer |
3,000 | $373K | Performance Shares | adopted Aug 29, 2024 | none found |
| Dec 29, 2025 | DANIEL O'DAY Officer, Director |
10,000 | $1.2M | Performance Shares | adopted Feb 28, 2025 | none found |
| Dec 15, 2025 | JOHANNA MERCIER Officer |
3,000 | $366K | Performance Shares | adopted Feb 20, 2025 | none found |
| Dec 15, 2025 | ANDREW DICKINSON Officer |
3,000 | $366K | Performance Shares; Restricted Stock | adopted Aug 29, 2024 | none found |
| Nov 28, 2025 | DANIEL O'DAY Officer, Director |
10,000 | $1.3M | Restricted Stock | adopted Feb 28, 2025 | none found |
| Nov 28, 2025 | JEFFREY BLUESTONE Director |
5,000 | $625K | Stock Option Exercise | none given | none found |
| Nov 26, 2025 | KELLY KRAMER Director |
5,611 | $713K | Exercise of Stock Options | adopted Aug 27, 2025 | none found |
| Nov 17, 2025 | JOHANNA MERCIER Officer |
28,000 | $3.5M | Performance Shares; Stock Option Exercise | adopted Feb 20, 2025 | none found |
| Nov 17, 2025 | ANDREW DICKINSON Officer |
2,500 | $313K | Restricted Stock | adopted Aug 29, 2024 | none found |
| Nov 13, 2025 | DIANE E WILFONG Officer |
3,500 | $445K | Stock Option Exercise | none given | none found |
| Nov 12, 2025 | DEBORAH TELMAN Officer |
55,646 | $6.8M | Exercise of Stock Options; Restricted Stock Units | adopted Aug 13, 2025 | none found |
| Oct 28, 2025 | DANIEL ODAY Officer, Director |
10,000 | $1.2M | Restricted Stock | adopted Feb 28, 2025 | none found |
Show the other 38 notices
From the Form 144 XML filed with the SEC, since Oct 28, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.